BLTE
Belite Bio (BLTE)
$00
About Belite Bio (BLTE)
Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.
Details
Daily high
$157.25
Daily low
$153.53
Price at open
$154.58
52 Week High
$162.00
52 Week Low
$49.00
Market cap
5.4B
Dividend yield
0.00%
Volume
368,592
Avg. volume
325,916
P/E ratio
-81.26
Belite Bio News
Details
Daily high
$157.25
Daily low
$153.53
Price at open
$154.58
52 Week High
$162.00
52 Week Low
$49.00
Market cap
5.4B
Dividend yield
0.00%
Volume
368,592
Avg. volume
325,916
P/E ratio
-81.26